CIK 0000014272
- Large accelerated filer
BRISTOL MYERS SQUIBB CO
Sign in to watch- Ticker
- BMY
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 220790350
- Phone
- +1 609-252-4621
- Business address
- ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543
Securities
- BMY Bristol-Myers Squibb Company Common Stock NYSE
- CELG-RI Rights NYSE
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $677,826
- in 3 filings
Net −$677,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-31 | YALE PHYLLIS R Director | Grant or award · Deferred Share Units | +462.14 | $73.03 | $34K | 14,855.16 |
| 2022-03-31 | Haller Julia A Director | Grant or award · Deferred Share Units | +462.14 | $73.03 | $34K | 15,107.7 |
| 2022-03-31 | Arduini Peter J Director | Grant or award · Deferred Share Units | +462.14 | $73.03 | $34K | 38,266.11 |
| 2022-03-31 | Rice Derica W Director | Grant or award · Deferred Share Units | +496.37 | $73.03 | $36K | 10,858.92 |
| 2022-03-22 | Caforio Giovanni Board Chair and CEO | Gift | −420 | 581,104.33 | ||
| 2022-03-21 | Caforio Giovanni Board Chair and CEO | Sale | −25,000 | $71.52 | $1.8M | 581,524.33 |
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Sale | −31,331 | $69.27 | $2.2M | 46,308 |
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise | +21,288 | $66.35 | $1.4M | 67,596 |
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise | +5,294 | $55.52 | $294K | 72,890 |
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise | +12,233 | $54.29 | $664K | 85,123 |
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise | +8,490 | $38.41 | $326K | 93,613 |
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Sale | −43,228 | $69.23 | $3.0M | 50,385 |
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −21,288 | 0 | ||
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −12,233 | 0 | ||
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −5,294 | 0 | ||
| 2022-03-16 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −8,490 | 8,491 | ||
| 2022-03-14 | Santiago Karen Murphy SVP & Controller | Sale | −6,577 | $69.20 | $455K | 16,704 |
| 2022-03-14 | BOERNER CHRISTOPHER S. EVP, Chief Commercial Officer | Sale | −29,532 | $69.20 | $2.0M | 41,966 |
| 2022-03-10 | Shanahan Karin EVP, Glob. Prod. Dev. & Supply | Grant or award · Market Share Units | +9,789 | 9,789 | ||
| 2022-03-10 | Shanahan Karin EVP, Glob. Prod. Dev. & Supply | Grant or award · Performance Shares | +14,683 | 14,683 |
Page 57 of 73 · 1,445 trades